Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 57.12 CNY -3.71%
Market Cap: 42.4B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Gross Margin
Hangzhou Tigermed Consulting Co Ltd

36.9%
Current
40%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
36.9%
=
Gross Profit
2.5B
/
Revenue
6.8B

Gross Margin Across Competitors

Country CN
Market Cap 44B CNY
Gross Margin
37%
Country US
Market Cap 1.2T USD
Gross Margin
55%
Country US
Market Cap 202.3B USD
Gross Margin
41%
Country US
Market Cap 166.6B USD
Gross Margin
60%
Country KR
Market Cap 66.8T KRW
Gross Margin
49%
Country CH
Market Cap 38.4B CHF
Gross Margin
29%
Country US
Market Cap 38.8B USD
Gross Margin
55%
Country US
Market Cap 36.3B USD
Gross Margin
35%
Country US
Market Cap 27B USD
Gross Margin
59%
Country US
Market Cap 24.1B USD
Gross Margin
35%
Country CN
Market Cap 164.6B CNY
Gross Margin
40%
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
42.4B CNY
Industry
Life Sciences Tools & Services

Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market. Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.

Intrinsic Value
69.85 CNY
Undervaluation 18%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
36.9%
=
Gross Profit
2.5B
/
Revenue
6.8B
What is the Gross Margin of Hangzhou Tigermed Consulting Co Ltd?

Based on Hangzhou Tigermed Consulting Co Ltd's most recent financial statements, the company has Gross Margin of 36.9%.